Skip to main content
Article thumbnail
Location of Repository

Neuroblastoma Cell Death is Induced by Inorganic Arsenic Trioxide (As2O3) and Inhibited by a Normal Human Bone Marrow Cell-Derived Factor

By Benjamin Gesundheit, Lea Malach, Reuven Or and Talia Hahn


Three phenotypically distinct cell types are present in human neuroblastomas (NB) and NB cell lines: I-type stem cells, N-type neuroblastic precursors, and S-type Schwannian/melanoblastic precursors. The stimulation of human N-type neuroblastoma cell proliferation by normal human bone marrow monocytic cell conditioned medium (BMCM) has been demonstrated in vitro, a finding consistent with the high frequency of bone marrow (BM) metastases in patients with advanced NB. Inorganic arsenic trioxide (As2O3), already clinically approved for the treatment of several hematological malignancies, is currently under investigation for NB. Recent studies show that As2O3 induces apoptosis in NB cells. We examined the impact of BMCM on growth and survival of As2O3-treated NB cell lines, to evaluate the response of cultured NB cell variants to regulatory agents. We studied the effect of BMCM on survival and clonogenic growth of eleven As2O3-treated NB cell lines grown in sparsely seeded, non-adherent, semi-solid cultures. As2O3 had a strong inhibitory effect on survival of all tested NB cell lines. BMCM augmented cell growth and survival and reversed the inhibitory action of As2O3 in all tested cell lines, but most strongly in N-type cells. While As2O3 effectively reduced survival of all tested NB cell lines, BMCM effectively impacted its inhibitory action. Better understanding of micro-environmental regulators affecting human NB tumor cell growth and survival may be seminal to the development of therapeutic strategies and clinically effective agents for this condition

Topics: Original Paper
Publisher: Springer Netherlands
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. Ackerstein A et al (2006) A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.
  2. (1991). An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT.
  3. (1999). Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
  4. (1999). Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase-3 in vitro.
  5. (2000). Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.
  6. (2005). Arsenic trioxide: an anti cancer missile with multiple warheads.
  7. (1997). Biology and treatment of neuroblastoma.
  8. (2002). Bone marrow derived factors support growth of N-type but not of melanocytic neuroblastoma cells.
  9. (2001). Comprehensive genetic and histopathological study reveals three types of human neuroblastoma tumors.
  10. (1994). Disruption of epithelial cell–matrix interactions induces apoptosis.
  11. (1998). Human bone marrow-derived mitogenic stimulation selective for breast carcinoma and neuroblastoma cells.
  12. (1999). Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.
  13. ØRa I, Pörn-Ares I et al (2004) Arsenic trioxideinduced death of neuroblastoma cells involves activation of bax and does not require p53.
  14. Påhlman S et al (2005) Multi-drug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia.
  15. Pietras A et al (2007) Arsenic trioxide and neuroblastoma cytotoxicity.
  16. (1980). Protein synthesis requires cell-surface contact while nuclear events respond to cell shape in anchorage-dependent fibroblasts.
  17. Thomas SK et al (2004) Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
  18. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.